跳至主要内容
临床试验/IRCT20151227025726N27
IRCT20151227025726N27招募中3 期

Evaluation of Efficacy and Safety of Inhaled Tocilizumab in Comparison with Intravenous Tocilizumab in Hospitalized Patients with COVID-19

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 100 years(—)
性别
All

入选标准

  • Patients between 18 and 100 years old.
  • Laboratory confirmed COVID-19 (Corona Virus Disease-19) with RT-PCR (Real-Time Polymerase Chain Reaction) or CT scan.
  • Have signed the consent form.
  • O2 saturation < 90% (at room air) or lung involvement >50% or respiratory rate >30
  • CRP > 75 mg/l
  • IL-6 > 15 pg/ml

排除标准

  • Allergy to Tocilizumab or one of the components of drug formulations.
  • ANC < 500 cells/mm
  • Pelatelet < 50000 cells/mm
  • Hepatic transaminases > 5 times normal range or mild increase in liver transaminases associated with signs and symptoms of liver disorder
  • History of malignancy
  • Diverticulitis
  • Positive procalcitonin and active infection (including latent or active tuberculosis infection)
  • Taking other rheumatoid drugs at the same time

研究者

相似试验